5-azacytidine
Showing 1 - 25 of >10,000
Squamous Cell Carcinoma of Head and Neck Trial (Combination 5-azacytidine and nivolumab, 5-azacytidine, Nivolumab)
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- Combination 5-azacytidine and nivolumab
- +2 more
- (no location specified)
Dec 7, 2022
Recurrent Ependymoma Trial in Houston (5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group
Recruiting
- Recurrent Ependymoma
- 5-Azacytidine (5-AZA) group 1
- +2 more
-
Houston, TexasThe University of Texas Health Science Center at Houston
Aug 17, 2022
Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)
Terminated
- Leukemia
- Brentuximab Vedotin
- 5-Azacytidine
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 7, 2022
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,
Recruiting
- Acute Myeloid Leukemia in Remission
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
AML, Childhood Trial in United States (Nivolumab, 5-azacytidine)
Active, not recruiting
- AML, Childhood
- Nivolumab
- 5-azacytidine
-
Los Angeles, California
- +11 more
Oct 10, 2022
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston
Active, not recruiting
- Chronic Myelomonocytic Leukemia-0
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2023
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM.D. Anderson Cancer Center
Apr 17, 2023
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life
Recruiting
- Secondary Myelodysplastic Syndrome
- Therapy-Related Myelodysplastic Syndrome
- Azacitidine
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 1, 2022
Acute Myeloid Leukemia Trial in Los Angeles, San Francisco (Azacitidine, Tagraxofusp-erzs)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- Tagraxofusp-erzs
-
Los Angeles, California
- +1 more
Jan 31, 2023
MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)
Recruiting
- Myelodysplastic Syndromes
- MDS/MPN Crossover Syndromes
- 5-azacytidine
- Decitabine
-
Cleveland, OhioCleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)
Recruiting
- Hodgkin's Lymphoma
-
Houston, TexasMD Anderson Cancer Center
Oct 5, 2022
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,
Completed
- Chronic Myelomonocytic Leukemia
- +3 more
- Azacitidine
- +2 more
-
Scottsdale, Arizona
- +3 more
Jan 12, 2023
Acute Myeloid Leukemia Trial in Chicago (Azacitidine, Biospecimen Collection, Bone Marrow Aspirate)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +5 more
-
Chicago, IllinoisNorthwestern University
Feb 16, 2023
Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Aug 12, 2022
Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)
Active, not recruiting
- Melanoma and Other Malignant Neoplasms of Skin
- Metastatic Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 31, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 10, 2023
Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2023
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- FLT3 Gene Mutation Negative
- +7 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 16, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Baltimore (Azacitidine, Sargramostim)
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Azacitidine
- Sargramostim
-
Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sep 23, 2022
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
Leukemia, Erythroblastic, Acute, MDS Trial in New York (5-Azacytidine, Fludarabine, Melphalan)
Completed
- Leukemia, Erythroblastic, Acute
- Myelodysplastic Syndromes
- 5-Azacytidine
- +4 more
-
New York, New YorkWeill Cornell Medical College
Aug 25, 2021